Detalles de la búsqueda
1.
Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.
Cancer
; 122(6): 875-83, 2016 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26709987
2.
The oncolytic virus, pelareorep, as a novel anticancer agent: a review.
Invest New Drugs
; 33(3): 761-74, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25693885
3.
The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.
BMC Cancer
; 15: 513, 2015 Jul 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26156229
4.
A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors.
JTO Clin Res Rep
; 5(2): 100619, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38328473
5.
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
Cancer Commun (Lond)
; 44(4): 455-468, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38421881
6.
Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer.
Cancer Lett
; 561: 216140, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36948240
7.
Targeting ALK Rearrangements in NSCLC: Current State of the Art.
Front Oncol
; 12: 863461, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35463328
8.
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 89(4): 487-497, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35247086
9.
Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC.
Onco Targets Ther
; 14: 3409-3415, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34079286
10.
Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.
Front Oncol
; 11: 754768, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34820326
11.
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
JAMA Oncol
; 7(11): 1617-1625, 2021 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34473194
12.
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
J Clin Oncol
; 39(12): 1349-1359, 2021 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33683919
13.
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing.
J Thorac Oncol
; 16(5): 827-839, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33588113
14.
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
Eur J Cancer
; 157: 198-213, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34536944
15.
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study.
J Thorac Oncol
; 15(3): 392-403, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31634667
16.
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
Lancet Respir Med
; 8(1): 45-53, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31628085
17.
Histologic subtype in NSCLC: does it matter?
Oncology (Williston Park)
; 23(13): 1133-40, 2009 Nov 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-20043461
18.
Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
Clin Cancer Res
; 13(10): 2876-81, 2007 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17504986
19.
A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma.
Cancers (Basel)
; 10(6)2018 May 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-29799479
20.
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Cancer Cell
; 33(5): 853-861.e4, 2018 05 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29731394